Skip to main content

Altimmune (US:ALT) — Company Overview, News & Financial Data

Altimmune logo
ALTAltimmune
Altimmune primary media
Company profile

About Altimmune

Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company focused on developing treatments that address critical needs in respiratory diseases and immune-modulating therapies. Their operations span the discovery, development, and commercialization of novel products to improve the lives of patients suffering from a range of conditions including obesity, liver diseases, and COVID-19. One of their flagship projects is a vaccine aimed at providing long-lasting protection against influenza, showcasing their commitment to tackling global health challenges. With a strategic approach to innovation and a dedicated team, Altimmune aims to advance its pipeline of promising candidates through the clinical stages, continually seeking to expand its impact on public health worldwide.

Snapshot

Public USOwnership
1997Year founded
69Employees
Gaithersburg, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Gaithersburg, US

Products and/or services of Altimmune

  • HepTcell, a therapeutic vaccine candidate for the treatment of chronic hepatitis B.
  • AdCOVID, a single-dose intranasal vaccine candidate for COVID-19.
  • T-COVID, an intranasal immunomodulator treatment for early COVID-19.
  • ALT-801, a novel GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH).
  • NasoShield, an anthrax vaccine candidate administered through a single intranasal dose.
  • NasoVAX, an intranasal influenza vaccine candidate designed to provide long-lasting protection.

Altimmune executive team

  • Dr. M. Scot Roberts Ph.D.Chief Scientific Officer
  • Mr. Jerome Benedict DursoChairman, CEO & President
  • Mr. Gregory L. Weaver CPA, M.B.A.Chief Financial Officer
  • Mr. Andrew Shutterly M.S.Principal Financial & Accounting Officer and Corporate Controller
  • Mr. Bertrand Georges Ph.D.Chief Technology Officer
  • Mr. Tony Blandin B.S.Vice President of Quality & Compliance Management
  • Ms. Robin E. Abrams J.D.General Counsel & Chief Legal Officer
  • Mr. Raymond M. Jordt M.B.A.Chief Business Officer
  • Ms. Linda M. RichardsonChief Commercial Officer
  • Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.Chief Medical Officer